Stock of the Day

September 14, 2023

Celularity (CELU)

$1.33
+$0.02 (+1.5%)
Market Cap: $42.51M

About Celularity

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Today's Trend

Celularity, Inc. (NASDAQ: CELU) is receiving mixed signals from its latest corporate developments. Potential strategic growth initiatives and a new board member provide upside catalysts, while financing-related dilution and ongoing execution risks may be weighing on sentiment.

  • Board appointment adds strategic visibility: Naveen Jain, founder and CEO of Viome Life Sciences, has joined Celularity’s board. His experience in biotechnology, personalized health and consumer technology could support the company’s commercial strategy and investor profile. Celularity Announces Naveen Jain to Join Board of Directors
  • Potential Asia-Pacific revenue opportunity: Celularity highlighted Fontaine Vitale’s anticipated Q1 2027 opening in Bali, Indonesia. The strategic partnership could expand access to regenerative-medicine services in the region and create a future commercial channel, although revenue benefits are not yet realized. Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
  • Quarterly results showed positive reported EPS: Celularity reported $0.02 earnings per share and quarterly revenue of $3.85 million. The results provide a near-term positive data point, but the relatively small revenue base leaves questions about the sustainability and scale of growth. Celularity Inc. Reports Earnings Results
  • Convertible financing creates dilution concerns: Celularity announced a $25 million convertible-notes financing. The proceeds may improve liquidity and fund operations, but conversion into shares could dilute existing shareholders and increase financing risk. Celularity Announces Convertible Notes Financing and Board Changes
  • Board transition adds uncertainty: Director Geoffrey Ling’s resignation, effective September 24, alongside the board refresh may prompt investors to monitor governance and execution continuity. Geoffrey Ling Resigns from Celularity Board
← Previous Stock of the DayNext Stock of the Day →